Alto Neuroscience’s (ANRO) ALTO-101, a novel PDE4 inhibitor, has shown promising results in Phase 1 studies for cognitive impairment associated with schizophrenia (CIAS). The transdermal patch formulation of ALTO-101 demonstrated improved tolerability and pharmacokinetics compared to oral administration. Alto plans a proof-of-concept study in CIAS patients in H1 2024, with top-line data expected in H2 2025.